Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2A6 | P11509 | 4/20 | 0.59 |
| ▸ | ASIC3 | Q9UHC3 | 1/20 | 0.59 |
| ▸ | LOXL2 | Q9Y4K0 | 1/20 | 0.59 |
| ▸ | AGXT | P21549 | 1/20 | 0.54 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.50 |
| ▸ | ADRA1D | P25100 | 2/20 | 0.42 |
| ▸ | CA2 | P00918 | 1/20 | 0.40 |
| ▸ | APP | P05067 | 1/20 | 0.39 |
| ▸ | MGLL | Q99685 | 1/20 | 0.38 |
| ▸ | IDH1 | O75874 | 1/20 | 0.38 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.38 |
| ▸ | BCL2L1 | Q07817 | 1/20 | 0.37 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27542201 | 0.82 | CYP2A6 (0.59) | CYP2A6ASIC3LOXL2AGXTADRB2 | |
| SCHEMBL8053051 | 0.78 | CYP2A6 (0.58) | CYP2A6ASIC3LOXL2AGXTADRB2 | |
| SCHEMBL12741 | 0.78 | CYP2A6 (0.58) | CYP2A6ASIC3LOXL2AGXTADRB2 | |
| SCHEMBL30416943 | 0.78 | CYP2A6 (0.58) | CYP2A6ASIC3LOXL2AGXTADRB2 | |
| SCHEMBL377160 | 0.78 | CYP2A6 (0.58) | CYP2A6ASIC3LOXL2AGXTADRB2 | |
| SCHEMBL10481498 | 0.77 | CYP2A6 (0.53) | CYP2A6ASIC3LOXL2AGXTADRB2 | |
| SCHEMBL3113989 | 0.75 | CYP2A6 (0.64) | CYP2A6ASIC3LOXL2AGXTADRB2 | |
| SCHEMBL240588 | 0.75 | CYP2A6 (1.00) | CYP2A6ASIC3LOXL2AGXTADRB2 | |
| SCHEMBL21480676 | 0.74 | CYP2A6 (0.46) | CYP2A6ASIC3LOXL2AGXTADRB2 | |
| SCHEMBL4961407 | 0.74 | CYP2A6 (0.69) | CYP2A6ASIC3LOXL2AGXTADRB2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7393865-B2 | Sleep inducing compounds and methods relating thereto | NEUROCRINE BIOSCIENCES, INC. (US) | 2008-07-01 | — | — | US | disclosed |
| EP-1651637-A1 | 3-AMINO CHROMAN AND 2-AMINO TETRALIN DERIVATIVES | Wyeth (US) | 2006-05-03 | — | — | EP | disclosed |
| WO-2006019497-A2 | SLEEP-INDUCING COMPOUNDS AND METHODS RELATED THERETO | NEUROCRINE BIOSCIENCES, INC. (US) | 2006-02-23 | — | — | WO | disclosed |
| US-20060014797-A1 | Sleep inducing compounds and methods relating thereto | NEUROCRINE BIOSCIENCES, INC. (US) | 2006-01-19 | — | — | US | disclosed |
| US-20050032873-A1 | 3-Amino chroman and 2-amino tetralin derivatives | WYETH (US) | 2005-02-10 | — | — | US | disclosed |
| WO-2005012291-A1 | 3-AMINO CHOMAN AND 2-AMINO TETRALIN DERIVATIVES | WYETH (US) | 2005-02-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050032873-A1 | 3-Amino chroman and 2-amino tetralin derivatives | TPH2, HTR2C, HTR7 | CYP2A6 2663/4885ASIC3 1202/4885LOXL2 2114/4885 |
| US-20060014797-A1 | Sleep inducing compounds and methods relating thereto | CHRM1, CNR1, HRH3 | CYP2A6 42/4885ASIC3 1630/4885LOXL2 1236/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.